Page 27 - Amgen News Today

Epoch Investment Partners Inc. cut its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 47.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,870 shares of the medical research company’s stock after selling 62,821 shares during the quarter. Epoch […]

Epoch Investment Partners Inc. cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 47.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 68,870 shares of the medical research company’s stock after selling 62,821 shares during the period. […]

Cetera Advisor Networks LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 109,371 shares of the medical research company’s stock after acquiring an additional 588 shares during the […]

Cetera Advisor Networks LLC grew its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 109,371 shares of the medical research company’s stock after buying an additional 588 shares during the quarter. Cetera Advisor Networks LLC’s holdings in Amgen were worth $31,501,000 at […]

Dermatologists say the study will lead to further research regarding how salt may play a role in the skin condition.

Peapack Gladstone Financial Corp lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 109,521 shares of the medical research company’s stock after buying an additional 313 shares during […]

The new proprietary cell line development platform combines a robust cell line, transposon technology with high throughput clone screening and single cell imaging to deliver highly efficient

The monoclonal antibody Uplizna met key endpoints in a phase 3 trial for the treatment of IgG4-related disease, marking the first time a placebo-controlled study has shown benefit in the condition, according to a press release from Amgen.Topline results from the double-blind, randomized trial, called MITIGATE, demonstrated an 87% reduced risk for IgG4-related disease (IgG4-RD) flare in patients

Cornerstone Advisory LLC raised its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,504 shares of the medical research company’s stock after buying an additional 99 shares during the […]

Neoadjuvant nivolumab with chemotherapy led to durable EFS benefit and a trend toward improved OS vs chemotherapy alone in patients with resectable NSCLC.